Sirukumab 50 mg

DRUG4 trials

Sponsors

Janssen Pharmaceutical K.K., Janssen Research & Development, LLC

Conditions

Arthritis, RheumatoidDepressive Disorder, Major

Phase 2

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

CompletedNCT02473289

Janssen Research & Development, LLCDepressive Disorder, Major

Start: 2015-07-23End: 2018-05-22Updated: 2025-04-29

Phase 3

A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine

CompletedNCT01689532

Janssen Pharmaceutical K.K.Arthritis, Rheumatoid

Start: 2012-11-30End: 2015-03-31Updated: 2016-10-27

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

CompletedNCT01856309

Janssen Research & Development, LLCArthritis, Rheumatoid

Start: 2013-08-07End: 2018-04-30Updated: 2019-05-06

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

CompletedNCT02019472

Janssen Research & Development, LLCArthritis, Rheumatoid

Start: 2014-04-04End: 2016-08-17Updated: 2017-10-26

Related Papers

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)

RMD Open2021-01-0117 citations

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.

2018-03-0715 citations

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.

2018-02-2622 citations